abstract |
Disclosed is the use of (-)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol for the production of a medicament for the transepicutaneous treatment of Restless Leg Syndrome, wherein the medicament may be in the form of a transdermal therapeutic system (TDS) comprising a backing layer that is inert with respect to the components of the matrix, a self-adhesive matrix layer containing (-)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthol, and a protective film to be removed before use. |